The US has been ranked as the country that contributes most to global biopharmaceutical innovation through the use of its policies.
Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
Pharmaceutical company Teva is set to re-brand itself as part of its plan to build “a new breed of healthcare company”.
Drugs made by pharmaceutical companies including Abbvie, Gilead, and Merck are set to achieve “blockbuster” status by 2020, according to a report.
Pharmaceutical companies including Cipla and Natco Pharma have signed a sub-licensing deal enabling them to produce a generic version of Bristol Myers Squibb’s hepatitis C drug Daclatasvir.
An individual working at India-based healthcare organisation Micro Labs has launched a mobile app which obtains relevant data on patents for pharmaceutical and biotechnology industry professionals.
Roche has settled its patent litigation dispute with India-based Glenmark Pharmaceuticals centring on cancer drug Tarceva.
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.
Australia-based law firm Piper Alderman has hired Julian Grover as a special counsel in the firm’s intellectual property practice.
US President Barack Obama has been urged by several non-government organisations to permanently exempt the world’s least developed countries from having to grant patents for pharmaceutical products.